ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal



    EMERYVILLE, Calif., Oct. 7 /CNW/ -- ProGenTech Limited, a life sciences &
diagnostics company based in Shanghai, China and Emeryville, CA has signed a
licensing agreement with Human Genetic Signatures, a Sydney, Australia based
life science company to gain access to key hospital-acquired infection
targets, payment terms were not disclosed.
    Under the terms of the agreement, Human Genetic Signatures will develop
assays for MRSA, MSSA, VRE and C. difficile which will then be further
integrated into the ProGenTech Entura platforms. It is anticipated that manual
assays for these initial targets will be taken to the FDA during 2009 followed
by fully integrated and automated versions of the assays in 2010. Launching
these assays will mark ProGenTech's initial foray into the molecular
diagnostics market.
    Dr. Trevor Hawkins, the Chairman & CEO of ProGenTech said, "We are very
excited to be working with Human Genetic Signatures to develop and
commercialize these assays. The advantages of our 'Press play and walk
away(TM)' Entura systems together with the Human Genetic Signatures' 3base(TM)
simplification technology will provide a valuable solution to the underserved
hospital-acquired infections market."
    "Our 3base(TM) assay technology is a natural fit with the current and
future Entura systems," said Angus Hastie, CEO of Human Genetic Signatures.
"Market trends are indicating that fast and easy to use modular platforms are
a powerful path forward for molecular diagnostics. ProGenTech's platform
vision in concert with a menu empowered by 3base(TM) assays will deliver new
clinical benefits and the complete diagnostics package to this burgeoning
market."
    The key advantage of ProGenTech's Entura platforms is that they greatly
reduce the total hands on time historically associated with sample
preparation. The Entura uses a unique cassette-based approach in which all
reagents for RNA, DNA or protein applications are pre-loaded in the cassette.
The user simply adds their samples to the cassettes, loads the cassettes into
the system, presses play, and walks away. The initial focus for ProGenTech has
been on developing automated solutions for Systems Biology life science
applications. This new relationship with Human Genetic Signatures marks the
formal launch of ProGenTech's Applied Sciences business which will take
products and solutions into the Molecular Diagnostics, Forensics and
Immunoassay market segments.
    The Human Genetic Signatures' proprietary 3base(TM) technology employs a
powerful base modification technique that greatly simplifies the detection of
highly variant microorganisms. Easily adaptable to routine assay preparation
and amplification methodologies, 3base(TM) can reduce the need for prohibitive
multiplexing or cumbersome array-based alternatives. Whilst 3base(TM) can be
used for the detection of any microbial target, it is even more useful for
detecting pathogens with multiple subtypes or rapidly changing resistance
traits. This partnership marks Human Genetic Signatures' entry into the
commercial clinical diagnostics market.
    
    About ProGenTech
    
    ProGenTech is a life science and diagnostics company based in Shanghai,
Suzhou and Emeryville, California. Established in 2005, the company has 80
employees today. Its first product, the Entura, was launched in Asia in
November 2007.  Additional information about ProGenTech can be found at
http://www.progentech.com.
    
    About Human Genetic Signatures
    
    Human Genetic Signatures is a life science company based in Sydney,
Australia. The company has been involved in microbial detection and human
methylation signatures since 2001. It has sought patent protection and
published methods for a variety of applications in these fields and is
involved in kit distribution and licensing its technologies. Additional
information about Human Genetic Signatures can be found at
http://www.geneticsignatures.com.




For further information:

For further information: Trevor Hawkins, CEO of ProGenTech Limited,
+1-925-640-0479 Web Site: http://www.progentech.com                
http://www.geneticsignatures.com

Organization Profile

PROGENTECH LIMITED

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890